HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock.

ESPR has been the subject of several other research reports. Needham & Company LLC cut their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Bank of America cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $2.90 to $2.50 in a report on Thursday, June 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics presently has an average rating of “Hold” and a consensus price target of $8.17.

Esperion Therapeutics Trading Up 5.6 %

Shares of ESPR traded up $0.09 during trading hours on Wednesday, reaching $1.70. The stock had a trading volume of 1,440,191 shares, compared to its average volume of 6,473,477. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40. The company has a market capitalization of $322.10 million, a price-to-earnings ratio of -1.72 and a beta of 1.00. The firm has a 50-day simple moving average of $1.87 and a 200 day simple moving average of $2.20.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. On average, equities analysts forecast that Esperion Therapeutics will post -0.04 EPS for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently made changes to their positions in ESPR. Capital Advisors Wealth Management LLC increased its holdings in shares of Esperion Therapeutics by 22.9% during the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 5,000 shares in the last quarter. Summit Financial LLC raised its holdings in Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 6,823 shares during the period. National Bank of Canada FI lifted its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Esperion Therapeutics by 1.0% during the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock valued at $3,373,000 after acquiring an additional 11,494 shares during the period. Finally, SG Americas Securities LLC raised its stake in Esperion Therapeutics by 45.3% during the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 11,658 shares during the period. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.